You can buy now, pay later for weight-loss drugs: Here's what you need to know
Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...
Fierce Pharma4d
Novo Nordisk offers cheaper Wegovy for all cash-paying patients at retail pharmacy
Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients
Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
PsyPost on MSN1d
Ozempic may reduce alcohol craving and consumption, new study finds
A new clinical trial suggests that semaglutide — the active ingredient in the widely used drugs Ozempic and Wegovy — may help ...
Managed Healthcare Executive4d
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies
Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...
Becker's Hospital Review3d
Novo Nordisk expands access to reduced-cost Wegovy
Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...
New Scientist on MSN1d
The Ozempic era is only just beginning
In the past year, treatments such as Wegovy, Mounjaro and Zepbound have become household names. But there are many questions ...
STAT3d
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.